Tissue treated with Allied Healthcare Group's ADAPT tissue engineering technology showed significantly reduced calcification in preclinical trials. [ + ]

Cancer treatment development company Patrys (ASX:PAB) has raised $3.4m in an oversubscribed placement to fund clinical trials for its antibody-based products. [ + ]

CBio appoints new chairman, interim MD; AusBiotech CEO joins Research Australia board; Timothy Waugh named Hatchtech CEO.

The National Health and Medical Research Council has issued its annual slew of Excellent Awards for 2011-2012, handing out accolades to some of the nation's top life scientists. [ + ]

Groundbreaking protein and cell biology research has discovered a new way to alter the survival of cancer cells by targeting active sarcoma kinase signalling.

The Australian Academy of Science urged the Federal Government to increase its efforts to attract and retain university students in science and mathematics.

Sydney researchers have discovered a new population of adult stem cells in the heart which could augment the development of new regeneration and repair therapies for people who have suffered heart attack or heart failure - the leading cause of death in Australia.

AusBiotech will be lobbying for a greater emphasis on biopharma and medical devices on the newly established Prime Minister's Taskforce on Manufacturing. [ + ]

Biotechnology Advisory Council will advise the government on current and emerging opportunities and threats to the biotechnology sector and aid in implementation of policy. [ + ]

The UC Division of Nephrology/Hypertension has used a fluorospectrometer to detect GFR in mice.

Victorian biopharma NeuProtect has added AstraZeneca's venture capital subsidiary, MedImmune Ventures, as a new investor. [ + ]

AusBiotech CEO, Dr Anna Lavelle, has been appointed to the Board of Research Australia, effective from the annual general meeting held recently. [ + ]

The Garvan's Professor David James challenges many assumptions about diabetes, its causes and treatments, including whether obesity is always a bad thing. [ + ]

Immuron (ASX:IMC) has secured a multi-market distribution deal worth up to C$115.5 million ($112.7m) for its debut OTC antibody product, Travelan. [ + ]

The Federal Government is conducting a first-of-its-kind study to gauge the level of privately funded clinical research activity in Australia. [ + ]